Submit Your Feeds

Business News • PR NewsWire • Study Finds Treatment with Metreleptin Improved Diabetes and Lipid Control in Patients with Partial Lipodystrophy

Study Finds Treatment with Metreleptin Improved Diabetes and Lipid Control in Patients with Partial Lipodystrophy
Study Finds Treatment with Metreleptin Improved Diabetes and Lipid Control in Patients with Partial Lipodystrophy

SAN DIEGO, June 4, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced results from a study that showed treatment with metreleptin, an investigational treatment that is an analog of the human hormone leptin, improved diabetes and lipid control in patients with partial li

View More : http://www.prnewswire.com/news-releases/study-finds-treatment-with-metreleptin-improved-diabetes-and-lipid-control-in-pa...
Releted News by prnewswire
Learning ZoneXpress Unveils USDA MyPlate Products to Use in the Classroom
Sanofi's Investigational Semuloparin in Cancer Patients Initiating Chemotherapy Shows a 64% Risk Reduction in Life-Threatening Venous Thrombo-Embolism
Sanofi's Investigational Semuloparin in Cancer Patients Initiating Chemotherapy Shows a 64 % Risk Reduction in Life-Threatening Venous Thrombo-Embolism
Study Finds Treatment with Metreleptin Improved Diabetes and Lipid Control in Patients with Partial Lipodystrophy
Full Speed Ahead! The National WWII Museum Unveils New $3.2 Million Restoration Pavilion
NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
Late-Breaking ASCO Data Demonstrate Circulating Tumor Cells as Potential Biomarker for Metastatic Prostate Cancer Clinical Trials
Home Sitemap Contact Us
© businessNewsNewsNews.com